Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Potato builds software that bridges scientific research and laboratory execution, enabling research teams to move from hypothesis to experiment to learning faster by automating the manual processes between scientific intent and real-world lab work.
2 investors
Reaxbio develops a chemoproteomics platform that identifies and targets novel protein sites for drug discovery across disease-relevant biological contexts. The platform enables small molecule discovery for virtually any protein using proprietary chemical tools and high-throughput screening capabilities.
2 investors
Rebel Medicine develops preclinical investigational drugs and wound care products designed to provide pain relief without opioids. The company targets postoperative and wound care patients through patented drug delivery technologies for local anesthetic applications.
2 investors
ReBio develops targeted, locally delivered therapies for ocular oncology, using its proprietary SiSu conjugate platform to program drug exposure for eye diseases. Its lead program, RBP-01, is a SiSu-conjugated PKC inhibitor for uveal melanoma delivered via intravitreal injection, with additional programs targeting retinoblastoma, glaucoma, and post-op ocular inflammation.
2 investors
Recor Medical develops the Paradise Ultrasound Renal Denervation system, a therapy that uses ultrasound technology to lower blood pressure in patients with hypertension. Founded in 2009 and now part of Otsuka Medical Devices, the company brings its hypertension treatment to physicians and patients worldwide.
2 investors
RedRidge Bio discovers and develops biparatopic antibodies (antibodies that bind two sites on a single protein), including biparatopic antibody-drug conjugates, as therapeutics for oncology and autoimmune diseases. The company uses high-throughput technologies and structural/disease biology to engineer and select antibody candidates for liquid and solid tumors and for inflammatory and autoimmune conditions.
2 investors
Red Arrow Therapeutics develops cancer therapies using a proprietary nanopolymer drug-delivery system for programmable encapsulation and release of biologics such as peptides, antibodies, and proteins. It aims to build a pipeline of polymer-drug conjugate cancer drugs with targeted tumor delivery and reduced off-tumor toxicity.
2 investors
Software platform to improve drug discovery
2 investors
ReGelTec develops injectable hydrogel technology for the repair of the nucleus pulposus of the intervertebral disc, targeting interventional pain management and spine care. The company is a medical device (MedTech) startup combining academic research in crosslinked polymers with experienced medical device executives.
2 investors
Regor is a drug discovery company that uses a computational platform (rCARD) to identify and optimize preclinical small-molecule candidates in metabolism, oncology, and immunology, which it licenses to pharmaceutical companies for clinical development. Its pipeline includes RGT-075, an oral GLP-1R agonist for obesity and type 2 diabetes, and next-generation CDK inhibitors for breast cancer.
2 investors
Improving patients' lives by accelerating development and commercialization of medicines that matter.
2 investors
Relief Cardiovascular develops transcatheter smart implant systems for volume management in congestive heart failure, including the Relief System, a preload-modulating implant for inferior vena cava flow modulation with autonomous hemodynamic monitoring. It targets heart failure patients with diuretic-resistant congestion whose needs are inadequately met by pharmaceuticals and legacy devices.
2 investors
Remedy Pharmaceuticals is a pharmaceutical company developing Cirara, an investigational drug studied in clinical trials for patients who have suffered a stroke. It focuses on treatments for serious neurological conditions.
2 investors
Remedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer. Its lead clinical candidate, RPT1G, is a hyperbolic inhibitor designed to reduce NAMPT activity while avoiding the toxicity that has limited earlier attempts.
2 investors
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD). Its pipeline targets the underlying biology of ADPKD across a range of mutations with the goal of halting and reversing disease progression.
2 investors
2 investors
2 investors
Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.
2 investors
Resalis Therapeutics develops antisense oligonucleotide therapies targeting microRNA pathways for metabolic disorders. The company is advancing RES-010, a treatment candidate for obesity, fatty liver disease, and related metabolic disorders.
2 investors
ResearchHub is a platform that connects researchers, funders, and the public to facilitate open science through transparent peer review, public preregistration, and decentralized funding mechanisms. The platform uses a native token (ResearchCoin) to reward scientific work including research funding, peer review, replication, and discussion.
2 investors
Reset Pharma is a CNS-focused pharmaceutical company developing psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases. It holds an exclusive worldwide license from NYU Langone Health for related intellectual property.
2 investors
2 investors
ResistanceBio develops treatments to address drug resistance in cancer patients.
2 investors
Resistell develops a nanomotion-based diagnostic device for rapid phenotypic antibiotic susceptibility testing (AST), aimed at accelerating detection of antibiotic resistance in hospital settings. The Swiss company's IVD product is intended for clinical microbiology use with bacterial pathogens.
2 investors